NCT02819596 2024-11-04
CALYPSO
Queen Mary University of London
Phase 2 Completed
Clinical Trials
3 trialsNCT00378482 2024-08-22
A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.
AstraZeneca
Phase 2 Completed
NCT03598816 2020-08-13
PIVOT-RCC
Washington University School of Medicine
Phase 2 Withdrawn